Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)
Articolo
Data di Pubblicazione:
2013
Tipologia CRIS:
Articolo su Rivista
Elenco autori:
O'Brien, Me; Gaafar, Rm; Popat, S; Grossi, F; Price, A; Talbot, Dc; Cufer, T; Ottensmeier, C; Danson, S; Pallis, A; Hasan, B; Van Meerbeeck, Jp; Baas, P
Link alla scheda completa:
Pubblicato in: